Estrogen augmentation in schizophrenia: A quantitative review of current evidence

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 179-184

  Begemann, Marieke J H ^a   Dekker, Caroline F ^a   van Lunenburg, Mari ^a   Sommer, Iris E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Estradiol; Estrogens; Estrone; Schizophrenia; Treatment

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; AUGMENTATION INDEX; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; ESTROGEN BLOOD LEVEL; FEMALE; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; LIMBIC SYSTEM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEOCORTEX; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SYSTEMATIC REVIEW; WOMEN'S HEALTH;

DOUBLE-BLIND METHOD; ESTROGENS; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 84866900342     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.016     Document Type: Article

References (61)

1. Akhondzadeh S., Nejatisafa A.A., Amini H., Mohammadi M.R., Larijani B., Kashani L., Raisi F., Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1007-1012.
2. Aleman A., Kahn R.S., Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch. Gen. Psychiatry 2003, 60:565-571.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Organisation, Washington, DC. Fourth Edition.
4. Arevalo M.A., Santos-Galindo M., Lagunas N., Azcoitia I., Garcia-Segura L.M. Selective estrogen receptor modulators as brain therapeutic agents. J. Mol. Endocrinol. 2011, 46:R1-R9.
5. Bergemann N., Parzer P., Runnebaum B., Resch F., Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 2007, 37:1427-1436.
6. Bergemann N., Parzer P., Jaggy S., Auler B., Mundt C., Maier-Braunleder S. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr. Bull. 2008, 34:1172-1181.
7. Borenstein M., Hedges L., Higgins J., Rothstein H. Comprehensive Meta Analysis Version 2 2005, Biostat Inc., Engelwood, NJ.
8. Braendle W., Breckwoldt M., Kuhl H., Riecher-Rössler A., Rohde A., Rüther E. Sexualhormone und Psyche - Ergebnisse des 2. Interdisziplinären Frankfurter Gesprächs zur Kontrazeption. Frauenarzt 2001, 42:154-160.
9. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33:1013-1022.
10. Burkman R., Schlesselman J.J., Zieman M. Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 2004, 190:S5-S22.
11. Chua W.L., de Izquierdo S.A., Kulkarni J., Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst. Rev. 2005, 1:CD004719.
12. Coromina Sadurni M., Rodie J.U., De Montagut L.M., Sanchez A.M. The use of oral contraceptives as a prevention of recurrent premenstrual psychosis. Psychiatry Res. 2009, 170:290-291.
13. Cotton S.M., Lambert M., Schimmelmann B.G., Foley D.L., Morley K.I., McGorry P.D., Conus P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr. Res. 2009, 114:17-24.
14. Dennerstein L., Judd F., Davies B. Psychosis and the menstrual cycle. Med. J. Aust. 1983, 1524-1526.
15. Dumas J.A., Kutz A.M., Naylor M.R., Johnson J.V., Newhouse P.A. Increased memory load-related frontal activation after estradiol treatment in postmenopausal women. Horm. Behav. 2010, 58:929-935.
16. Dunlap W.P., Cortina J.M., Vaslow J.B., Burke M.J. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol. Methods 1996, 1:170-177.
17. Felthous A.R., Robinson D.B., Conroy R.W. Prevention of recurrent menstrual psychosis by an oral contraceptive. Am. J. Psychiatry 1980, 137:245-246.
18. Gattaz W.F., Vogel P., Riecher-Rössler A., Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol. Psychiatry 1994, 36:137-139.
19. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J. Clin. Psychiatry 2006, 67(S9):3-8.
20. Grigoriadis S., Seeman M.V. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can. J. Psychiatry 2002, 47:437-442.
21. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003, 28:17-54.
22. Hannaford P.C., Iversen L., Macfarlane T.V., Elliott A.M., Angus V., Lee A.J. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. Br. Med. J. 2010, 340:c927.
23. Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
24. Hughes Z.A., Liu F., Marquis K., Muniz L., Pangalos M.N., Ring R.H., Whiteside G.J., Brandon N.J. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr. Mol. Pharmacol. 2009, 2:215-236.
25. Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology 2007, 27:604-608.
26. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
27. Ko Y.H., Joe S.H., Cho W., Park J.H., Lee J.J., Jung I.K., Kim L., Kim S.H. Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. Int. J. Psychiatry Clin. Pract. 2006, 10:97-104.
28. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen - a potential treatment for schizophrenia. Schizophr. Res. 2001, 48:137-144.
29. Kulkarni J., de Castella A., Fitzgerald P.B., Gurvich C.T., Bailey M., Bartholomeusz C., Burger H. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 2008, 65:955-960.
30. Kulkarni J., Gurvich C., Lee S.J., Gilbert H., Gavrilidis E., de Castella A., Berk M., Dodd S., Fitzgerald P.B., Davis S.R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35:1142-1147.
31. Kulkarni J., de Castella A., Headey B., Marston N., Sinclair K., Lee S., Gurvich C., Fitzgerald P.B., Burger H. Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?. Schizophr. Res. 2011, 125:278-283.
32. Kulkarni J., Hayes E., Gavrilidis E. Hormones and schizophrenia. Curr. Opin. Psychiatry 2012, 25:89-95.
33. Lethaby A., Suckling J., Barlow D., Farquhar C.M., Jepson R.G., Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst. Rev. 2004, CD000402.
34. Leung A., Chue P. Sex differences in schizophrenia: a review of the literature. Acta Psychiatr. Scand. 2000, 401:3-38.
35. Lipsey M.W., Wilson D.B. Practical Meta-Analysis 2001, Sage, Thousand Oaks, CA.
36. Louzã M.R., Marques A.P., Elkis H., Bassit D., Diegoli M., Gattaz W.F. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr. Res. 2004, 66:97-100.
37. Lu Y., Ma H., Malone K.E., Norman S.A., Sullivan-Halley J., Strom B.L., Simon M.S., Marchbanks P.A., McDonald J.A., West D.W., Henderson K.D., Deapen D., Ursin G., Bernstein L. Oral contraceptive use and survival in women with invasive breast cancer. Cancer Epidemiol. Biomark. 2011, 20:1391-1397.
38. Manzoli L., De Vito C., Marzuillo C., Boccia A., Villary P. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 2012, 35:191-205.
39. Markham J.A. Sex steroids and schizophrenia. Rev. Endocr. Metab. Disord. 2011, May 21. 10.1007/s11154-011-9184-2.
40. McGrath J., Saha S., Welham J., Saadi O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004, 2:13-35.
41. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P.R.I.S.M.A. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009, 339:b2535.
42. Morgan V.A., Castle D.J., Jablensky A.V. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders. Aust. N. Z. J. Psychiatry 2008, 42:74-82.
43. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:790-812.
44. Österlund M.K., Hurd Y.L. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog. Neurobiol. 2001, 64:251-267.
45. Peri A., Benvenuti S., Luciani P., Deledda C., Cellai I. Membrane cholesterol as a mediator of the neuroprotective effects of estrogens. Neuroscience 2011, March 10. 10.1016/j.neuroscience.2011.03.011.
46. Riecher-Rössler A. Oestrogen effects in schizophrenia and their potential therapeutic implications - review. Arch. Womens Ment. Health 2002, 5:111-118.
47. Riecher-Rössler A., Häfner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr. Scand. 2000, 102(S407):58-62.
48. Riecher-Rössler A., Häfner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994, 20:203-214.
49. Rosenthal R. The 'file drawer problem' and tolerance for null effects. Psychol. Bull. 1979, 86:638-641.
50. Rosenthal R. Meta-Analytic Procedures of Social Research 1984, Sage, London.
51. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., Ko M., LaCroix A.Z., Margolis K., Stefanick M.L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J. Am. Med. Assoc. 2007, 297:1465-1477.
52. Schiff R., Bulpitt C.J., Wesnes K.A., Rajkumar C. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology 2005, 30:309-315.
53. Shadish W.R., Haddock C.K. Combining estimates of effect size. The Handbook of Research Synthesis 1994, 261-281. Russell Sage Foundation, New York. H. Cooper, L.V. Hedges (Eds.).
54. Taylor G.T., Maloney S., Dearborn J., Weiss J. Hormones in the mentally disturbed brain: steroids and peptides in the development and treatment of psychopathology. Cent. Nerv. Syst. Agents Med. Chem. 2009, 9:331-360.
55. Turgeon J.L., McDonnell D.P., Martin K.A., Wise P.M. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004, 304:1269-1273.
56. Usall J., Huerta-Ramos E., Iniesta R., Cobo J., Araya S., Roca M., Serrano-Blanco A., Teba F., Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 2011, 72:1552-1557.
57. Vessey M., Yeates D., Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010, 82:221-229.
58. Von Krafft-Ebing G. Undersuchungen über Irresein zur Zeit der Menstruation: Ein klinischer Beitrag zur Lehre vom periodischen Irresein. Arch. Psychiatr. 1878, 8:65-107.
59. Wise P.M., Dubal D.B., Wilson M.E., Rau S.W., Böttner M. Minireview: neuroprotective effects of estrogen- new insights into mechanisms of action. Endocrinology 2001, 142:969-973.
60. World Health Organization The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines 1992, World Health Organization, Geneva, Switzerland.
61. Wroolie T.E., Kenna H.A., Williams K.E., Powers B.N., Holcomb M., Khaylis A., Rasgon N.L. Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17?-estradiol versus conjugated equine estrogens. Am. J. Geriatr. Psychiatry 2011, 19:792-802.